West Pharmaceutical Services, I — Earnings Quality Grade A
WST · Healthcare
Strong financial health
Screening Summary
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 68 days, change -2 days YoY
AR growth 4.0% vs revenue growth 6.3%
Revenue 6.3%, CFFO 15.5%. Cash follows revenue
Expense Quality
Inventory 17.7% vs COGS 4.0%. Normal
CapEx growth -24.2% vs revenue 6.3%. Normal
SG&A/Gross Profit = 35.7%. Normal
Gross margin 35.9%, change +1.4pp. Stable
Cash Flow Quality
CFFO/NI = 1.53. Profits backed by cash
FCF $0.5B, FCF/NI = 0.95
Accruals ratio = -6.1%. Low accruals
Cash $0.8B covers debt $0.3B
Balance Sheet Health
Goodwill+Intangibles $0.1B = 4% of equity. Manageable
Debt/EBITDA = 0.4x. Healthy
Other assets 7.8% vs revenue 6.3%. Normal
Write-offs up 1400% YoY
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change 1% YoY. Normal
Manipulation Score
M-Score = -2.79 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-09